Literature DB >> 8476039

Contribution of muscle and liver to glucose-fatty acid cycle in humans.

C Saloranta1, V Koivisto, E Widén, K Falholt, R A DeFronzo, M Härkönen, L Groop.   

Abstract

To examine the influence of elevated free fatty acid (FFA) levels on hepatic glucose production (HGP) and oxidative and nonoxidative pathways of glucose metabolism, 12 healthy subjects participated in two euglycemic insulin-clamp studies performed with and without infusion of Intralipid plus heparin. To elucidate the role of skeletal muscle in this putative interaction, we performed muscle biopsies for the measurement of activities of glycogen synthase (GS), pyruvate dehydrogenase (PDH), and carnitine palmitoyltransferase (CPT). Infusion of Intralipid plus heparin caused an increase in plasma FFA concentrations and rate of lipid oxidation (measured by indirect calorimetry) that was not inhibited by insulin. Suppression of HGP by insulin was impaired by elevated plasma FFA levels. Furthermore, the increase in plasma FFA was associated with a 20% reduction in total glucose metabolism (P < 0.01), which was completely accounted for by a reduction in the rate of glucose oxidation. Although the fractional activity of GS was increased by insulin, elevation of plasma FFA had no influence on this key enzyme of glycogen synthesis. In addition, the activities of PDH and CPT were uninfluenced by the elevation of FFA, suggesting that oxidative processes in skeletal muscle were not a major target for the operative glucose-fatty acid cycle under the current conditions. Taken together, the data indicate that the interaction between FFA and glucose metabolism also involves impaired suppression of HGP by insulin.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8476039     DOI: 10.1152/ajpendo.1993.264.4.E599

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  12 in total

Review 1.  Correction of dysfunctional fatty acid metabolism using peroxisome proliferator activated receptor gamma agonists.

Authors:  Nicholas D Oakes; Bengt Ljung; Germán Camejo
Journal:  J R Soc Med       Date:  2002       Impact factor: 5.344

2.  Glucose tolerance and free fatty acid metabolism in adults with variations in TCF7L2 rs7903146.

Authors:  Jin Lu; Ron T Varghese; Lianzhen Zhou; Adrian Vella; Michael D Jensen
Journal:  Metabolism       Date:  2016-12-09       Impact factor: 8.694

3.  The biochemical basis of increased hepatic glucose production in a mouse model of type 2 (non-insulin-dependent) diabetes mellitus.

Authors:  S Andrikopoulos; J Proietto
Journal:  Diabetologia       Date:  1995-12       Impact factor: 10.122

4.  Mechanism of free fatty acid-induced insulin resistance in humans.

Authors:  M Roden; T B Price; G Perseghin; K F Petersen; D L Rothman; G W Cline; G I Shulman
Journal:  J Clin Invest       Date:  1996-06-15       Impact factor: 14.808

5.  Insulin signaling is required for insulin's direct and indirect action on hepatic glucose production.

Authors:  Simon J Fisher; C Ronald Kahn
Journal:  J Clin Invest       Date:  2003-02       Impact factor: 14.808

6.  High levels of palmitic acid lead to insulin resistance due to changes in the level of phosphorylation of the insulin receptor and insulin receptor substrate-1.

Authors:  Rosalía Reynoso; Luis M Salgado; Víctor Calderón
Journal:  Mol Cell Biochem       Date:  2003-04       Impact factor: 3.396

7.  Mechanisms of fatty acid-induced inhibition of glucose uptake.

Authors:  G Boden; X Chen; J Ruiz; J V White; L Rossetti
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

8.  Non-esterified fatty acids regulate lipid and glucose oxidation and glycogen synthesis in healthy man.

Authors:  P Ebeling; V A Koivisto
Journal:  Diabetologia       Date:  1994-02       Impact factor: 10.122

Review 9.  Fat-induced liver insulin resistance.

Authors:  Pankaj Shah; Ananda Basu; Robert Rizza
Journal:  Curr Diab Rep       Date:  2003-06       Impact factor: 4.810

10.  Effect of lipid oxidation on the regulation of glucose utilization in obese patients.

Authors:  A Golay; J P Felber; D Jallut; R Munger; J Ruiz; E Jéquier
Journal:  Acta Diabetol       Date:  1995-03       Impact factor: 4.280

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.